Lutetium (177Lu) Edotreotide

7 trials 4 recruiting Orphan designation

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

2 Completed trials

5 Sponsors

11 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 4 Phase II: 2 Phase I (Other): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Gastroenteropancreatic neuroendocrine tumour disease 2 Central nervous system neoplasm 1 Lymphoma 1 Rhabdomyosarcoma 1 Gastrointestinal stromal tumour 1 Peripheral primitive neuroectodermal tumour of soft tissue 1 Ewing's sarcoma 1 Neuroendocrine tumour 1

Sponsors using this IMP

ITM Solucin GmbH 3 Grupo Espanol De Tumores Neuroendocrinos 1 Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. 1 Region Midtjylland 1 Region Skane 1

All trials

7 total

Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospect… Pending

2024-519183-40-00 Phase II 1 country Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
A trial to determine the dose, and evaluate the safety and pharmacokinetics of lutetium Lu 177 edotreotide in children with somatostatin rec… Recruiting

2024-512831-66-00 Phase I (Other) 3 countries ITM Solucin GmbH
Dosimetry based PRRT versus standard dose PRRT with Lu-177-DOTATOC in NEN patients- a randomized study; a step towards tailored PRRT. Recruiting

2024-517240-62-00 Phase II 1 country Region Midtjylland
177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting

2022-502154-13-00 Phase III 4 countries Grupo Espanol De Tumores Neuroendocrinos
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An open-label, multi-center, randomized phase III trial comparing safety a… Recruiting

2023-508572-11-00 Phase III 1 country Region Skane
Lutetium (177Lu) Edotreotide versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuro… Ended

2024-510812-64-00 Phase III 5 countries ITM Solucin GmbH
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended

2023-510444-21-00 Phase III 9 countries ITM Solucin GmbH

Showing 1–7 of 7 trials

← All drugs A–Z